School of Medicine
Showing 471-480 of 631 Results
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team assesses approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program. -
Kavitha Ramchandran
Clinical Professor, Medicine - Oncology
Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.
In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs. -
Jianghong Rao
Professor of Radiology (Molecular Imaging Program at Stanford) and, by courtesy, of Chemistry
Current Research and Scholarly InterestsProbe chemistry and nanotechnology for molecular imaging and diagnostics
-
Lawrence Recht, MD
Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsOur laboratory focuses on two interrelated projects: (1) assessment of glioma development within the framework of the multistage model of carcinogenesis through utilization of the rodent model of ENU neurocarcinogenesis; and (2) assessment of stem cell specification and pluripotency using an embryonic stem cell model system in which neural differentiation is induced.
-
David Rehkopf
Director, Stanford Center on Longevity, Professor of Epidemiology and Population Health, of Sociology, of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics, and of Health Policy
BioI am a social epidemiologist and Professor in the Department of Epidemiology and Population Health, the Department of Sociology, and the Division of Primary Care and Population Health in the Department of Medicine. I joined the Stanford University faculty in 2011.
My research examines the health implications of the myriad decisions made every day by corporations and governments—decisions that profoundly shape the social and economic worlds in which we live and work. Although these changes are often invisible in daily life, seemingly minor actions and decisions can serve as structural nudges that produce better or worse health at the population level. My work documents the health consequences of corporate and governmental decisions, providing evidence that can help the public and policymakers develop new strategies to promote health and well-being. Across this work, I focus particularly on the implications of these exposures for health inequalities.
Because policy and programmatic changes can take decades to influence health, my research also includes more basic work to identify biological signals that may serve as early warning signs of systemic disease, particularly accelerated aging. I examine how social and economic policy changes affect a range of early markers of disease and aging, with a recent focus on DNA methylation. I am supported by several grants from the National Institute on Aging and the National Institute on Minority Health and Health Disparities to develop more sensitive approaches for understanding the health effects of social and economic policy changes. -
David A. Relman
Thomas C. and Joan M. Merigan Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsMy investigative program focuses on human-microbe interactions and human microbial ecology, and primarily concerns the ecology of human indigenous microbial communities; a secondary interest concerns the classification of humans with systemic infectious diseases, based on features of genome-wide gene transcript abundance patterns and pther aspects of the host response.
